Navigation Links
Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
Date:8/5/2008

NEW HAVEN, Conn., Aug. 5 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, announced today that company representatives are giving three presentations at two conferences this week.

Gordon Research Conference on Medicinal Chemistry, August 3-8

Ashoke Bhattacharjee, Ph.D, Senior Scientist, presented at the Gordon Research Conference on Medicinal Chemistry this week at Colby Sawyer College, New London, NH. Dr. Bhattacharjee introduced Rib-X's enhanced macrolide program in a poster session titled, "Structure-Based Drug Design Targeting Infectious Disease: Overcoming Resistance and Extending the Antimicrobial Spectrum of Macrolide Antibiotics." In his presentation on August 3 and 4, Dr. Bhattacharjee highlighted how the combination of structural insights from X-ray crystallographic studies of known and new antibiotics bound to the bacterial 50S ribosomal subunit with data-driven computational chemistry tools allows for a fresh look at macrolide antibiotics.

Additionally, Graham Johnson, Ph.D, Chief Research Officer of Rib-X will give a presentation in the "Late-Breaking Topics" session, Thursday, August 7. The title of the talk is "Discovery and Clinical Development of radezolid (RX-1741), a Designer Oxazolidinone" and will highlight the company's proprietary discovery process utilizing structural, computational and chemistry approaches; radezolid has distinct physical properties as well as a promising efficacy and safety profile.

Drug Discovery & Development of Innovative Therapeutics World Conference, August 4-7

Joseph DeVito, Ph.D, Associate Director, Discovery Biology, Rib-X Pharmaceuticals, Inc., is presenting Rib-X's RX-04 program at IBC's 12th Annual Drug Discovery & Development of Innovative Therapeutics World Conference Technology Conference today at 11:00 AM ET at The World Trade Center Boston and Seaport Hotel, Boston, MA. Dr. DeVito will highlight RX-04 in a presentation titled "Using Structure-Based Discovery to Define Novel Antibiotics Targeting the 50S Ribosomal Subunit." RX-04 is Rib-X's de novo design of three completely new series of antibacterials showing promising activity against serious multidrug resistant Gram-negative pathogens, including, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Klebsiella pneumoniae, Acinetobacter baumanii and Escherichia coli.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in the fundamental process of protein synthesis. Many known, commercially valuable antibiotics bind to the ribosome, including those used to treat both community-acquired and hospital-acquired pathogens. The Company's integrated research strategy, which combines state of the art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotic classes. The Company currently has two programs in human clinical trials, the radezolid (RX-1741) designer oxazolidinone program as an oral/IV agent to treat serious hospital Gram-positive infections and the delafloxacin, (RX-3341) program, a next generation fluoroquinolone, active against a broad spectrum of bacteria, including methicillin-resistant Staphylococcus aureus. Additionally, the Company has multiple drug discovery programs. The first of these is a rapidly developing discovery program that has identified a new chemical classes of antibiotics active against multi-drug resistant Gram negative bacteria in the hospital. The second of these programs is focused on design and development of an IV and orally active macrolide for treatment of infections in the nursing home and hospital setting, including those caused by MRSA and enterococci.

For more information on the ribosome and the Rib-X mission, please visit the Company website at http://www.rib-x.com.


'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
2. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
3. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
4. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
5. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
6. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
9. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
10. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
11. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , January 19, 2017 Incretin Mimetics/GLP-1 Agonists, ... Others The global anti-obesity drugs market is ... half of the forecast period and CAGR of 38.7% in the ... grow at a CAGR of 32.8% from 2016 to 2027. The ... 2021, and $24,063 million in 2027. ...
(Date:1/19/2017)... 2017 James Gilbart ... Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to European Oncology ... an article by James Gilbart and ...
(Date:1/19/2017)... , Jan. 19, 2017   Science Exchange , ... to announce that the first five replication studies ... have been published in eLife today. Despite intense ... the first practical evaluation of reproducibility rates that ... studies. Unlike other assessments of reproducibility, the results ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... ... engineers, and scientists from around the world, announces the launch of its newly ... and easy portal to research breakthroughs and trending news, vital information on upcoming ...
(Date:1/19/2017)... ... January 19, 2017 , ... Remote ... recently unveiled impressive transportable capabilities with their iMedHD2™ Portable Teleultrasound System. ... to RMT technology that delivers HD, dynamic, streaming ultrasound images and video to ...
(Date:1/19/2017)... ... January 19, 2017 , ... WholeHealth is ... year. Drs. Alexander Paziotopoulos, Andrew Petersen and Trish Henrie-Barrus will be present Saturday ... clinic’s leading recovery program. , “We know it’s easy to get carried ...
(Date:1/19/2017)... Scotch Plains, NJ (PRWEB) , ... January 19, ... ... a board certified dermatologist by the American Board of Dermatology and fellowship trained ... Institute of the National Institutes of Health, Dr. Li completed his internship in ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... Clinical Conductor CTMS, which provides a modern CTMS workflow designed to seamlessly integrate ... information has been condensed to a single page, maximizing usability and improving efficiency ...
Breaking Medicine News(10 mins):